Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
Just Biotherapeutics is developing an integrated technology platform to accelerate the development and manufacturing of high-quality biologics at a significantly lower cost, to broaden global biologic access.
Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More
By Natalie Revelle October 27, 2016 In 2010 at the Bill & Melinda Gates Foundation, Natalie Revelle was a relatively new financial manager supporting the global health team. Bill Gates was present at a meeting, where Gavi, the global alliance Read More
The Stanford Social Innovation Review explores how the Bill & Melinda Gates Foundation uses strategic investments for social impact. Read the full report here. Chapters: Philanthropy’s New Tools for Innovation and Impact Leveraging the Balance Sheet Neglected No More Unintended Read More